We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TER:NASDAQTeradyne, Inc. Analysis

Data as of 2026-05-26 - not real-time

$358.44

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Teradyne (TER) closed the day at $358.44, comfortably above its 20‑day ($352.50) and 50‑day ($341.90) SMAs, confirming a bullish price action despite a bearish MACD signal and a neutral RSI of 52.4. The stock’s beta of 2.78 and a 30‑day volatility of roughly 92% signal high sensitivity to market swings, while volume trends are tapering, suggesting a potential slowdown in buying pressure. Fundamentally, TER posted an explosive 87% revenue growth and robust margins (gross 58.7%, operating 37.6%, profit 22.6%), yet its trailing PE of 66.6× dwarfs the industry average of 39.5×, and the DCF‑derived fair value of $68.8 implies severe overvaluation. The dividend yield sits at a modest 0.15% with a payout ratio under 10%, indicating sustainability but limited income appeal. Recent material news highlights a record‑breaking Q1 2026 beat driven by AI‑related demand and a strategic partnership with Flex to expand automation, which should fuel near‑term momentum. However, the stark gap between market price and intrinsic valuation, combined with high beta and volatility, suggests caution for investors seeking price appreciation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price trading above short‑term SMAs but MACD turning bearish
  • High beta and volatility increasing downside risk
  • Strong Q1 earnings supporting near‑term stability

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained double‑digit revenue growth and expanding AI demand
  • Strategic partnership with Flex enhancing robotics exposure
  • Robust operating margins and low payout ratio enabling reinvestment

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Fundamental overvaluation relative to DCF and peers
  • Continued high beta making long‑run price trajectory uncertain
  • Dividend sustainability but limited yield reduces total return appeal

Key Metrics & Analysis

Financial Health

Revenue Growth87.00%
Profit Margin22.55%
P/E Ratio66.6
ROE28.75%
ROA15.83%
Debt/Equity2.62
P/B Ratio20.0
Op. Cash Flow$777.9M
Free Cash Flow$298.3M
Industry P/E39.5

Technical Analysis

TrendBullish
RSI52.4
Support$301.86
Resistance$421.44
MA 20$352.50
MA 50$341.90
MA 200$228.44
MACDBearish
VolumeDecreasing
Fear & Greed Index91.57

Valuation

Fair Value$68.82
Target Price$369.53
Upside/Downside3.09%
GradeOvervalued
TypeGrowth
Dividend Yield0.15%

Risk Assessment

Beta2.78
Volatility91.86%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.